In vivo imaging of astrocytosis in Alzheimer's disease: an (11)C-L: -deuteriodeprenyl and PIB PET study.
(2011) In European Journal of Nuclear Medicine and Molecular Imaging 38(12). p.2202-2208- Abstract
- PURPOSE: Astrocytosis is an important feature of the neuropathology of Alzheimer's disease (AD), yet there is currently no way of detecting this phenomenon in vivo. METHODS: In this study we examine the retention of the positron emission tomography (PET) tracer (11)C-L: -deuteriodeprenyl (DED), thought to bind activated astrocytes, in 9 patients with moderate to severe AD compared with 11 healthy controls. As a measure of amyloid load, (11)C-labelled Pittsburgh Compound B (PIB) retention was determined. RESULTS: Results show a significantly higher (11)C-L: -DED retention in the frontal (35.1% increase, p = 0.001), parietal (35.2%, p = 0.001), temporal (30.9%, p = 0.0001) and medial temporal lobes (22.3%, p = 0.001) in AD compared to... (More)
- PURPOSE: Astrocytosis is an important feature of the neuropathology of Alzheimer's disease (AD), yet there is currently no way of detecting this phenomenon in vivo. METHODS: In this study we examine the retention of the positron emission tomography (PET) tracer (11)C-L: -deuteriodeprenyl (DED), thought to bind activated astrocytes, in 9 patients with moderate to severe AD compared with 11 healthy controls. As a measure of amyloid load, (11)C-labelled Pittsburgh Compound B (PIB) retention was determined. RESULTS: Results show a significantly higher (11)C-L: -DED retention in the frontal (35.1% increase, p = 0.001), parietal (35.2%, p = 0.001), temporal (30.9%, p = 0.0001) and medial temporal lobes (22.3%, p = 0.001) in AD compared to healthy controls after blood flow correction. DED retention in the sensorimotor and occipital cortices, and in white matter and subcortical structures, did not differ between groups. There was a moderate but statistically significant (r = 0.492, p = 0.01) correlation between DED and PIB retention values. CONCLUSION: Our conclusion is that DED may serve as an in vivo marker for astrocytosis in AD, providing a window into intermediate processes between amyloidosis and neuronal loss and a means of monitoring immunotherapy. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2150844
- author
- Santillo, Alexander
LU
; Gambini, Juan Pablo ; Lannfelt, Lars ; Långström, Bengt ; Luohija, Ulla-Maja ; Kilander, Lena and Engler, Henry
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Pittsburgh Compound B, C-11-L-deuteriodeprenyl, Astrocytosis, Alzheimer's disease, Positron emission tomography
- in
- European Journal of Nuclear Medicine and Molecular Imaging
- volume
- 38
- issue
- 12
- pages
- 2202 - 2208
- publisher
- Springer
- external identifiers
-
- wos:000297732700012
- pmid:21853308
- scopus:84856235427
- ISSN
- 1619-7070
- DOI
- 10.1007/s00259-011-1895-9
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Psychogeriatrics (013304000)
- id
- 1a6fbdda-c426-4c31-a6ff-d3b46dcf02a2 (old id 2150844)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21853308?dopt=Abstract
- date added to LUP
- 2016-04-01 09:52:41
- date last changed
- 2025-04-04 14:41:01
@article{1a6fbdda-c426-4c31-a6ff-d3b46dcf02a2, abstract = {{PURPOSE: Astrocytosis is an important feature of the neuropathology of Alzheimer's disease (AD), yet there is currently no way of detecting this phenomenon in vivo. METHODS: In this study we examine the retention of the positron emission tomography (PET) tracer (11)C-L: -deuteriodeprenyl (DED), thought to bind activated astrocytes, in 9 patients with moderate to severe AD compared with 11 healthy controls. As a measure of amyloid load, (11)C-labelled Pittsburgh Compound B (PIB) retention was determined. RESULTS: Results show a significantly higher (11)C-L: -DED retention in the frontal (35.1% increase, p = 0.001), parietal (35.2%, p = 0.001), temporal (30.9%, p = 0.0001) and medial temporal lobes (22.3%, p = 0.001) in AD compared to healthy controls after blood flow correction. DED retention in the sensorimotor and occipital cortices, and in white matter and subcortical structures, did not differ between groups. There was a moderate but statistically significant (r = 0.492, p = 0.01) correlation between DED and PIB retention values. CONCLUSION: Our conclusion is that DED may serve as an in vivo marker for astrocytosis in AD, providing a window into intermediate processes between amyloidosis and neuronal loss and a means of monitoring immunotherapy.}}, author = {{Santillo, Alexander and Gambini, Juan Pablo and Lannfelt, Lars and Långström, Bengt and Luohija, Ulla-Maja and Kilander, Lena and Engler, Henry}}, issn = {{1619-7070}}, keywords = {{Pittsburgh Compound B; C-11-L-deuteriodeprenyl; Astrocytosis; Alzheimer's disease; Positron emission tomography}}, language = {{eng}}, number = {{12}}, pages = {{2202--2208}}, publisher = {{Springer}}, series = {{European Journal of Nuclear Medicine and Molecular Imaging}}, title = {{In vivo imaging of astrocytosis in Alzheimer's disease: an (11)C-L: -deuteriodeprenyl and PIB PET study.}}, url = {{https://lup.lub.lu.se/search/files/1347417/2295361.pdf}}, doi = {{10.1007/s00259-011-1895-9}}, volume = {{38}}, year = {{2011}}, }